BR9705117A - Lipídeos catiônicos para terapia de gene - Google Patents

Lipídeos catiônicos para terapia de gene

Info

Publication number
BR9705117A
BR9705117A BR9705117A BR9705117A BR9705117A BR 9705117 A BR9705117 A BR 9705117A BR 9705117 A BR9705117 A BR 9705117A BR 9705117 A BR9705117 A BR 9705117A BR 9705117 A BR9705117 A BR 9705117A
Authority
BR
Brazil
Prior art keywords
gene therapy
cationic lipids
lipids
cationic
therapy
Prior art date
Application number
BR9705117A
Other languages
English (en)
Inventor
John Otto Link
John Joseph Nestor Jr
Gary Allen Peltz
Paula Nanette Belloni
Donald Roy Hirschfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9705117A publication Critical patent/BR9705117A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24Y being a hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
BR9705117A 1996-10-22 1997-10-22 Lipídeos catiônicos para terapia de gene BR9705117A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2958196P 1996-10-22 1996-10-22

Publications (1)

Publication Number Publication Date
BR9705117A true BR9705117A (pt) 1998-09-15

Family

ID=21849783

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9705117A BR9705117A (pt) 1996-10-22 1997-10-22 Lipídeos catiônicos para terapia de gene

Country Status (7)

Country Link
US (1) US6034137A (pt)
EP (1) EP0846680A1 (pt)
JP (1) JPH10152461A (pt)
CN (1) CN1068585C (pt)
AR (1) AR010013A1 (pt)
BR (1) BR9705117A (pt)
CA (1) CA2217550A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
ATE383331T1 (de) 1998-11-12 2008-01-15 Invitrogen Corp Transportreagentien
FR2788275B1 (fr) * 1999-01-11 2002-06-14 Lipha ((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique
US7294511B2 (en) * 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
EP1514943B1 (en) * 2002-06-14 2006-10-11 Consejo Superior De Investigaciones Cientificas Non-invasive analysis and detection of micro-organisms in dairy products contained in laminated paper or carton containers, using elastic waves by means of dry coupling
GB0315783D0 (en) * 2003-07-04 2003-08-13 Norferm Da Use
CN1968714B (zh) 2004-05-05 2013-10-16 赛伦斯治疗公司 脂质、脂质复合物及其应用
WO2007008220A2 (en) * 2004-08-05 2007-01-18 Baylor Research Institute Gene or drug delivery system
PL1830888T3 (pl) 2004-12-27 2015-12-31 Silence Therapeutics Gmbh Kompleksy lipidowe pokryte PEG i ich wykorzystanie
EP1746084B1 (en) * 2005-07-22 2010-11-17 Novagali Pharma S.A. Process for the preparation of saturated or unsaturated primary fatty amines
EP2049658A2 (en) 2006-07-21 2009-04-22 Silence Therapeutics AG Means for inhibiting the expression of protein kinase 3
BRPI0714762A2 (pt) 2006-09-27 2014-12-23 Paolo Botti Meios e métodos de aumento de entrega para sistemas biológicos
WO2009138806A1 (en) * 2008-05-13 2009-11-19 Dendrigen S.A. Novel liposome cocktail formulations containing doxorubicin and the potent multidrug resistance inhibitor amiodarone
JP2011520962A (ja) 2008-05-19 2011-07-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 新規カチオン性脂質を含む方法及び組成物
EP3698631A3 (en) * 2009-05-05 2020-11-25 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
SG177590A1 (en) * 2009-07-09 2012-03-29 Marina Biotech Inc Amphoteric liposomes comprising imino lipids
AU2011245987B2 (en) * 2010-04-28 2016-12-15 Kyowa Hakko Kirin Co., Ltd Cationic lipid
BR122022001262B1 (pt) 2010-11-15 2022-09-27 Life Technologies Corporation Compostos de transfecção contendo amina e complexo de transfecção
EP2532649B1 (en) 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
TWI594767B (zh) * 2011-12-12 2017-08-11 協和醱酵麒麟有限公司 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
US20140045913A1 (en) * 2011-12-12 2014-02-13 Kyowa Hakko Kirin Co., Ltd. Lipid nano particles comprising combination of cationic lipid
WO2014097178A1 (en) * 2012-12-18 2014-06-26 Jawaharlal Nehru Centre For Advanced Scientific Research Antimicrobial compounds, their synthesis and applications thereof
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
WO2016045732A1 (en) * 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
US11712407B2 (en) 2014-12-30 2023-08-01 Celltrion, Inc. Hybrid-type multi-lamellar nanostructure of epidermal growth factor and liposome and method for manufacturing same
AU2016285852B2 (en) 2015-06-29 2020-12-17 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3368507B1 (en) 2015-10-28 2022-12-07 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
EP3615510B1 (en) 2017-04-28 2024-03-27 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11639329B2 (en) 2017-08-16 2023-05-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US20210395188A1 (en) * 2018-10-18 2021-12-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
BR112021013654A2 (pt) 2019-01-11 2021-09-14 Acuitas Therapeutics, Inc. Lipídeos para liberação de nanopartículas lipídicas de agentes ativos
CN111087332B (zh) * 2019-12-11 2021-07-06 东南大学 一种阳离子氨基脂质及其合成方法与应用
WO2022016070A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
CA3143650A1 (en) * 2021-12-22 2023-06-22 Providence Therapeutics Holdings Inc. Lipids and compositions thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4926046B1 (pt) * 1969-12-30 1974-07-05
DE2808943A1 (de) * 1978-03-02 1979-09-06 Goldschmidt Ag Th Neue guanidiniumsalze, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende mikrobicide zubereitungen
JPS5754157A (en) * 1980-09-19 1982-03-31 Nippon Kayaku Co Ltd L-argininal derivative and its preparation
US4477428A (en) * 1982-08-26 1984-10-16 Johnson & Johnson Products, Inc. Oral compositions comprising N.sup.α,NG -diacyl derivatives of arginine
GB8312663D0 (en) * 1983-05-09 1983-06-15 Ici Plc Bisbiguanide compounds
GB8312662D0 (en) * 1983-05-09 1983-06-15 Ici Plc Polyether bisbiguanide
JPS60214768A (ja) * 1984-04-07 1985-10-28 Fujisawa Pharmaceut Co Ltd オリゴペプチド化合物
US5141751A (en) * 1988-06-29 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structures
US5478946A (en) * 1989-06-21 1995-12-26 Abbott Laboratories Guanidino compounds as regulators of nitric oxide synthase
US5654451B1 (en) * 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
EP0679153A4 (en) * 1993-01-14 1996-05-15 Magainin Pharma FINALLY MODIFIED AMINO ACIDS AND PEPTIDES.
WO1995014381A1 (en) * 1993-11-24 1995-06-01 Megabios Corporation Amphiphilic derivatives of guanidine
JPH07136604A (ja) * 1993-11-24 1995-05-30 Ebara Corp 洗浄方法及び装置
WO1995028377A1 (en) * 1994-04-18 1995-10-26 Abbott Laboratories Guanidine compounds as regulators of nitric oxide synthase
US5777153A (en) * 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
JP3163230B2 (ja) * 1995-03-13 2001-05-08 科学技術振興事業団 二次元分子パターンの作成方法

Also Published As

Publication number Publication date
MX9708111A (es) 1998-08-30
US6034137A (en) 2000-03-07
CA2217550A1 (en) 1998-04-22
CN1180697A (zh) 1998-05-06
CN1068585C (zh) 2001-07-18
EP0846680A1 (en) 1998-06-10
JPH10152461A (ja) 1998-06-09
AR010013A1 (es) 2000-05-17

Similar Documents

Publication Publication Date Title
BR9705117A (pt) Lipídeos catiônicos para terapia de gene
DE69815075D1 (de) Dimere kationische lipide auf dicystinbasis
BR9612533A (pt) Terapia de combinação para osteoporose
DE69735382D1 (de) Kationische reagenzien zür transfektion
PT849853E (pt) Consola para calhas de suporte
EP1015578A4 (en) THERAPEUTIC MOLECULES
ID24118A (id) Terapi gabungan
NO20004688L (no) Terapi ved østrogenassosierte lidelser
BR9605819A (pt) Apoio para cabeça
PT1113965E (pt) Acessorio para gargalo de garrafa
ID24275A (id) Terapi kombinasi
NO970172D0 (no) Kationiske amfifiler
PT907358E (pt) Terapia de distribuicao uniforme de droga
PT9493U (pt) Cabeca para esfregona
NO20006047D0 (no) Fremgangsmåte for genterapi
EP1037631A4 (en) HETEROCYCLIC CATIONIC FATS
BR9508281A (pt) Técnica para autenticação
BR9500251A (pt) Multi-contador para rodas
BR9700690A (pt) Banco para terapia neurológica
ES1031699Y (es) Envase para golosinas
BR9704122A (pt) Estimulador eletro-eletrônico para seios
BR9705606A (pt) Luminária para cromoterapia
BR9505158A (pt) Complexo inorgânico para tratamento de tumores
BR7701696U (pt) Disposição em suporte para fixação de rodízio
ES1029754Y (es) Base para enchufe electrico de seguridad.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.